文献速递妇科

一项多中心临床试验验证HE4、CA125、卵巢恶性肿瘤风险算法及恶性肿瘤风险指数

A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
PubMed 文献 · Gynecol Oncol · 2018-08-24

在瑞典西部六家医院连续纳入638例术前诊断为性质不明卵巢囊肿或盆腔肿瘤的女性,评估HE4、CA125、ROMA及RMI与最终病理诊断的符合度。结果提示CA125识别卵巢癌优于HE4,HE4识别良性病变更准确,可能有助于鉴别诊断、指导诊疗级别并减少过度治疗。

要点

  • 绝经后女性中RMI(>200)、ROMA(≥29.9)、CA125(>35 U/mL)、HE4(>140 pmol/L)的敏感度分别为89%、91%、92%、72%,特异度分别为80%、77%、80%、92%。
  • 绝经前女性中RMI、ROMA(≥11.6)、CA125、HE4(>70 pmol/L)的敏感度分别为87%、87%、96%、83%,特异度分别为90%、81%、60%、91%。
  • 作者认为CA125识别卵巢癌优于HE4,HE4更准确识别良性病变,并建议在日常实践中开展HE4检测。

核心结论

  • 作者认为CA125作为识别卵巢癌的生物标志物优于HE4,HE4更准确识别良性病变,可能有助于鉴别诊断、指导诊疗级别并减少过度治疗。
  • 该研究证实了此前单中心研究的结果,并建议在日常实践中开展HE4检测。

研究设计与样本

  • 多中心临床试验,瑞典西部六家医院从2013年9月至2016年2月连续纳入638例术前诊断为性质不明卵巢囊肿或盆腔肿瘤的女性。
  • 术前采集血清、经阴道超声数据及基本患者特征,计算生物标志物水平、ROMA和RMI,并与最终病理报告比较。

主要发现

  • 638例中良性肿瘤445例、交界性肿瘤31例、恶性肿瘤162例,上皮性卵巢癌总体发生率为21%。
  • 绝经后女性中RMI(>200)、ROMA(≥29.9)、CA125(>35 U/mL)、HE4(>140 pmol/L)的敏感度分别为89%、91%、92%、72%,特异度分别为80%、77%、80%、92%。
  • 绝经前女性中RMI、ROMA(≥11.6)、CA125、HE4(>70 pmol/L)的敏感度分别为87%、87%、96%、83%,特异度分别为90%、81%、60%、91%。
  • 绝经后女性中RMI与ROMA的诊断准确度(ROC AUC)分别为0.85和0.84,绝经前女性中分别为0.90和0.81。

关键数值与推荐

  • 绝经后女性:RMI>200、ROMA≥29.9、CA125>35 U/mL、HE4>140 pmol/L。
  • 绝经前女性:ROMA≥11.6、HE4>70 pmol/L。

临床怎么用

  • 作者建议在日常实践中开展HE4检测。
  • 作者认为HE4更准确识别良性病变,可能有助于鉴别诊断、指导诊疗级别并减少过度治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To validate, in a multicenter clinical trial, the performance of biomarkers and algorithms for differential diagnosis in a population of women diagnosed with an unknown ovarian cyst or pelvic tumor. METHODS: Six hospitals in Western Sweden consecutively enrolled 638 women from September 2013 to February 2016. Serum, transvaginal ultrasound data, and basic patient characteristics were collected preoperatively. Biomarker levels, risk of malignancy algorithm (ROMA), and risk of malignancy index (RMI) were calculated and compared with the final pathology report. RESULTS: Our sample of 638 patients had 445 benign, 31 borderline, and 162 malignant tumors recorded, and the overall incidence of epithelial ovarian cancer was 21%. In postmenopausal women, RMI (>200), ROMA (≥29.9), CA125 (>35 U/mL), and HE4 (>140 pmol/L) showed sensitivity at 89%, 91%, 92%, and 72%, respectively, and specificity at 80%, 77%, 80%, and 92%. In premenopausal women, sensitivity of RMI, ROMA (≥11.6), CA125, and HE4 (>70 pmol/L) was 87%, 87%, 96%, and 83%, respectively, and specificity was 90%, 81%, 60%, 91%. Diagnostic accuracy (ROC AUC) of RMI and ROMA in postmenopausal women was 0.85 and 0.84, and in premenopausal women, 0.90 and 0.81. CONCLUSION: Our results suggest that CA125 is superior to HE4 as a biomarker to identify women with ovarian cancer. HE4 more correctly identifies benign lesions, which may help in differential diagnoses to guide the level of care and decrease overtreatment. This study confirms prior results from single-center studies and suggests the implementation of HE4 measurement in daily practice.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lycke M, Kristjansdottir B, Sundfeldt K, et al. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018. PMID: 30149898. doi:10.1016/j.ygyno.2018.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。